103 results about "Receptor type" patented technology

The invention relates to a donor-recipient typed conjugated polymer containing two thiofuran and pyrrole and the preparation method and applications thereof. Using a construction mode of donor-recipient typed co polymerization for preparing the conjugated polymer can absorb action spectrum, cover UV-Visible and near infrared region to fully use sunlight. The donor uses a constitution unit of two thiofuran and pyrrole with a good plane performance, high density of electron cloud and easy preparation. The preparation of the conjugated polymer is easy, with absorbing spectrum in the UV-Visible and near infrared region of 300 to1000nm and the energy transforming efficiency being 3 percent. The performances of prepared solar batteries are respectively: white light (light intensity of 100mW / cm<2> ) irradiating, the open-circuit voltage is equal to 0.37 to 0.54 V; the short circuit current is equal to 6.69 to 13.8mA / cm<2>; the packing factor is equal to 0.35 to 0.44; and the efficiency of energy transformation is equal to 1 to 3 percent.

A variety of methods for assaying libraries of test compounds as ligands and / or substrates of transport proteins, including both carrier-type and receptor-type transport proteins, are provided. Both in vitro and in vivo screening methods are disclosed. Also provided are methods for screening DNA libraries to identify members that encode transport proteins. Pharmaceutical compositions including compounds identified via the screening methods are also provided.

A variety of methods for assaying libraries of test compounds as ligands and / or substrates of transport proteins, including both carrier-type and receptor-type transport proteins, are provided. Both in vitro and in vivo screening methods are disclosed. Also provided are methods for screening DNA libraries to identify members that encode transport proteins. Pharmaceutical compositions including compounds identified via the screening methods are also provided.

The present invention provides compounds for modulating receptor kinase activity, particularly ephrin and EGFR, and methods of treating diseases mediated by receptor kinase activity utilizing the compounds and pharmaceutical compositions thereof. Diseases mediated by receptor kinase activity include, but are not limited to, diseases characterized in part by abnormal levels of cell proliferation (i.e. tumor growth), programmed cell death (apoptosis), cell migration and invasion and angiogenesis associated with tumor growth. Compounds of the invention include “spectrum selective” kinase modulators, compounds that inhibit, regulate and / or modulate signal transduction across subfamilies of receptor-type tyrosine kinases, including ephrin and EGFR.

To provide a nucleic acid encoding a receptor protein kinase, wherein the nucleic acid has tandem duplication in a nucleotide sequence of a juxtamembrane and is useful for diagnosis of leukemia; a polypeptide encoded by the nucleic acid; an antibody capable of specifically binding to a region encoded by the nucleic acid having tandem duplication occurring in a nucleotide sequence of a juxtamembrane; a nucleic acid capable of specifically binding to the nucleic acid having tandem duplication occurring in a nucleotide sequence of a juxtamembrane; a method for detection of the nucleic acid encoding a receptor protein kinase; and a kit therefor. A nucleic acid encoding a receptor protein kinase, wherein the nucleic acid has tandem duplication in a nucleotide sequence of a juxtamembrane; a polypeptide encoded by the nucleic acid; an antibody capable of specifically binding to the portion of the polypeptide; a nucleic acid capable of specifically binding to the nucleic acid; a method for detection of the nucleic acid; and a kit for detection.

The present invention provides compounds for modulating receptor kinase activity, particularly ephrin and EGFR, and methods of treating diseases mediated by receptor kinase activity utilizing the compounds and pharmaceutical compositions thereof. Diseases mediated by receptor kinase activity include, but are not limited to, diseases characterized in part by abnormal levels of cell proliferation (i.e. tumor growth), programmed cell death (apoptosis), cell migration and invasion and angiogenesis associated with tumor growth. Compounds of the invention include “spectrum selective” kinase modulators, compounds that inhibit, regulate and / or modulate signal transduction across subfamilies of receptor-type tyrosine kinases, including ephrin and EGFR.

The invention relates to an electronic donor / receptor type norbornene monomer, as well as a polymer and a preparation method thereof. Being prepared from the electronic donor / receptor type norbornene monomer by means of ring-opening metathesis polymerization in the presence of a Grubbs ruthenium catalyst, the norbornene polymer disclosed by the invention has good stereoregularity and high Pi-Pi interaction between molecular chains, and contributes to charge transfer. The preparation method provided by the invention is simple and easy to implement and can realize regulation and control of performances by flexible transformation by a side chain substituent group, so the preparation method has wide application prospect in fields of photo-elements, electric elements, biomacromolecule, etc.

The present invention provides new compounds and methods for treating a disease responsive to inhibition of kinase activity, for example a disease responsive to inhibition of protein tyrosine kinase activity, for example a disease responsive to inhibition of protein tyrosine kinase activity of growth factor receptors, for example a disease responsive to inhibition of receptor type tyrosine kinase signaling, or for example, a disease responsive to inhibition of VEGF receptor signaling.

Disclosed herein are compositions for inactivating the human CCR5 gene comprising engineered LAGLIDADG homing endonucleases (LHEs) and their derivatives, particularly derived from members of the \-Onul subfamily of LHE. Polynucleotides encoding such endonucleases, vectors comprising said polynucleotides, cells comprising or having been treated with such endonucleases, and therapeutic compositions deriving therefrom are also provided.

A monoclonal antibody that binds to an extracellular domain of human receptor-type protein tyrosine phosphatase σ (human PTPRS), or a fragment including an antigen-binding region thereof.

A conjugate protein comprising an IL-2 and a soluble TGF-beta type II receptor type B and its use in cancer immunotherapy are described.

A conjugate protein comprising an IL-2 and a soluble TGF-beta type II receptor type B and its use in cancer immunotherapy are described.

The object of the present invention is to provide a method for efficiently producing vinegar that contains a higher concentration of acetic acid, wherein a gene involved in the acetic acid fermentation ability is obtained, the acetic acid fermentation ability of an acetic acid bacterium is improved by reducing or deleting the function of the protein encoded by the gene. An acetic acid bacterium with a remarkably improved acetic acid fermentation ability was obtained by obtaining genes encoding an acyl homoserine lactone synthase and an acyl homoserine lactone receptor-type transcription factor that are involved in the quorum-sensing system in the acetic acid bacterium, and modifying the genes so as to reduce or delete the function of the quorum-sensing system. Further provided is a method for more efficiently producing vinegar containing a higher concentration of acetic acid by using the acetic acid bacterium.

The present disclosure is based on the identification of biomarkers of combined genetic variants and imaging measurements, in predicting faster decline in cognitive measures and brain glucose metabolism in populations with Alzheimer's disease or those susceptible to developing Alzheimer's disease. The present disclosure provides a method of treating a patient with Alzheimer's disease (AD) or a subject susceptible to developing AD, comprising: (a) assaying a sample obtained from an early-stage AD patient or a subject susceptible to developing AD for the presence of a brain-derived neurotrophic factor (BDNF) gene mutation and / or a protein tyrosine phosphatase receptor-type, Z polypeptide 1 (Ptprz1) gene mutation; (b) determining whether the patient or subject is positive for brain amyloid-beta (Aβ), wherein the presence of brain Aβ in combination with the BDNF gene and / or Ptprz1 gene mutation correlates with a prediction of rapid cognitive decline; and (c) treating the patient or subject with early and aggressive therapy appropriate to treat AD with rapid cognitive decline.

Method for identifying myeloid or plasmacytoid dendritic cells provided by a mammal, stimulated or unstimulated, comprising the steps of: a) preparing a cell sample; b) contracting the cell sample myeloid or plasmacytoid dendritic cells to form a complex; c) detecting the complex; characterized in that the phosphatase is the Receptor type Tyrosine Phosphatase Gamma Protein (PTPRG), acting as a specific marker of said dendritic cells, and in that the compound is a polypeptide capable of selectively bind to the PTPRG or to a fragment thereof or to a oligonucleotide complementary to a PTPRG mRNA logonucleotide in such a manner as to allow the selective recognizing of the dendritic cells in the cell sample.

The invention provides methods of controlling pH variations during chromatography. In particular embodiments, the invention includes equilibrating and eluting proteins from chromatography resins have a solid phase that possesses a charged functional group on its backbone under controlled conditions of osmolarity and pH. The invention is particularly useful in the purification of proteins that are sensitive to pH transitions such as, for example, the IL-1 Receptor type II protein.

The mechanism by which pleiotrophin binds to the receptor protein tyrosine phosphatase β / ζ(RPTP β / ζ) is disclosed along with methods of modulating both pleiotrophin expression and signaling to treat, prevent and inhibit abnormal cell growth states. Specifically provided are methods of inhibiting tumor growth, promotion, metastasis, invasiveness and angiogenesis as well as methods of preventing or inhibiting cell adhesion.

The invention discloses a small molecular polypeptide TAT-siP-PTPN1-HA and application thereof in preparation of a medicament for treating or preventing senile dementia. An artificially synthesized TAT protein transduction structural domain and an siP-PTPN1-HA fusion protein polypeptide TAT-siP-PTPN1-HA are used, TAT can carry the siP-PTPN1-HA protein polypeptide to pass through a blood-brain carrier via blood to be absorbed by neurons, and by applying the small molecular polypeptide TAT-siP-PTPN1-HA to an in-vivo senile dementia model, the biological action of blocking the binding of miR-124 and protein tyrosine phosphatase, non-receptor type 1, PTPN1 3'-non-coding sequence (3'-untranslated region, 3'-UTR) can be effectively realized, the expression of PTPN1 is further effectively reversed, excessive phosphorylation of microtube-associated protein tau and amyloid protein deposition, as well as animal learning and memory disorders represented by an senile dementia model animal are improved, and a new direction is provided for further development of the medicaments for clinical treatment of senile dementia.

The invention discloses a fluorenyl donor / receptor type nano polymer as well as a preparation method and application thereof. In a nano grid polymer, a fluorenyl derivative is used as electron donor units in nano grid fragments, and the electron donor units and electron receptor units are arranged alternatively to form a square annular rigid structure. The preparation method comprises the following step: performing a polymerization reaction on a nano grid fragment (II) and a polymerization fragment (III) with preserved halogen end groups, thereby obtaining the polymer. The polymer material disclosed by the invention has the advantages that a synthesis mode is modularized, high extensibility and high thermal, electrochemical and optical stability can be achieved, film solvent dependency can be alleviated, large-scale soluble processing can be achieved, aperture sizes can be precisely adjusted and controlled, precise regulation and control on band gap and energy level arrangement can be achieved, and the like; and the polymer material has potential application prospects in fields of photoelectric functional materials for organic solar batteries, memories and memory resistors, sensors, detectors and the like.

The present invention relates to pyrazoloanthrones or functional derivatives or functional analogues thereof to activate MIS receptor-mediated downstream effects in a cell. In particular, the present invention relates to method to prevent and treat cancer that expresses MIS receptor type II (MISRII) by administering to a subject at least one pyrazoloanthrone or a functional derivative or a functional analogue thereof. Another aspect of the present invention relates to methods to lower plasma androgen levels in a subject, and / or for the treatment of a subject with a disease characterized by excess androgen, whereby the subject is administered at least one pyrazoloanthrone or a functional derivative or a functional analogue thereof. Another aspect provides pharmaceutical compositions comprising at least one pyrazoloanthrone or functional a derivative or a functional analogue thereof, and optionally with one or more additional agents such as chemotherapeutic agents. Another aspect of the present invention relates to methods to decrease the dose of a chemotherapeutic agent by administering the chemotherapeutic agent with a pyrazoloanthrone or a functional derivative or a functional analogue thereof that lowers the effective dose of the chemotherapeutic agent, such as for example, paclitaxel.

This invention relates to methods and compositions for overcoming the dose-dependent down regulation of interleukin 10 (IL-10) by expressing, in addition to an interleukin 10 (IL-10) peptide, an IL-10 receptor type 1 (IL-10R1) peptide. The methods have use in treating a variety of diseases and symptoms, including but not limited to neuropathic or chronic pain; symptoms and physiological damage associated with multiple sclerosis, spinal cord injury, ALS, neuroinflammation, arthritis and other diseases of the joint; and autoimmune diseases.

Discoveries are disclosed that show particular aspects of recombinant DNA technology can be used successfully to produce a hitherto unknown type of human Platelet-Derived Growth Factor (PDGF) receptor protein free of other PDGF receptors. These proteins can be produced from DNA segments in cells in various functional forms. These forms variously enable biochemical and functional studies of these novel receptors as well as production of antibodies. Means are described for determining the level of expression of genes for specific types of PDGF receptor proteins, for example, by measuring mRNA in cells with PDGF receptor type-specific DNA probes or by measuring antigen in biological samples with type-specific antibodies.

The present invention relates to modified recombinant human MIS protein which has improved cleavage and increased bioactivity and increased potency as compared to wild-type human MIS protein. Other aspects of the invention relate to methods to prevent and treat cancers, such as cancers that express the MIS receptor type II (MISRII) by administering to a subject a composition comprising a recombinant human MIS protein. Another aspect of the present invention relates to methods to lower plasma androgen levels in a subject, and / or for the treatment of a subject with a disease characterized by excess androgen. Another aspect provides pharmaceutical compositions and kits and methods for use comprising a recombinant human MIS protein. Another aspect of the present invention relates to methods to decrease the dose of a chemotherapeutic agent by administering the chemotherapeutic agent with the recombinant MIS protein that lowers the effective dose of the chemotherapeutic agent.

Provided herein are peptide inhibitors of the interaction between End Binding Protein 3 (EB3) and Inositol 1,4,5-Trisphosphate Receptor Type 3 (IP3R3). Also provided are methods and materials for treating lung injury, including acute lung injury, which may include hyperpermeability of lung vessels, vascular leakage, the development of edema, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, and nasal congestion.

The invention belongs to the field of pharmaceutical preparation, and relates to an albumin nano-particle preparation of a donor-receptor type fluorescent molecule containing an aggregation-induced emission group in a near infrared II region. By adopting an emulsifying high-pressure homogenization method, bovine serum albumin, human serum albumin or recombinant human serum albumin and the donor-receptor type fluorescent molecule containing the aggregation-induced emission group are processed so that nano-particles are prepared; albumin is bonded with the fluorescent molecule , so that rotation in the molecule is limited, molecular conformation is changed, and twisted intramolecularcharge transfer and aggregation-induced emission effect are changed, so that the nano-particle preparation having good fluorescence imaging and photothermal conversion is obtained. The nano-particle preparation can emit fluorescence in the near infrared II region under irradiation of infrared light, and a part of light energy is transformed into heat energy, and an image-guided photothermal therapy for cancers is realized. The albumin nano-particle preparation can be used for preparing a medicine for conducting fluorescence imaging and photothermal therapy in the near infrared II region (NIR-II, 1000nm to 1700nm), and the aim of integration of diagnosis and treatment is fulfilled.

To provide a nucleic acid encoding a receptor protein kinase, wherein the nucleic acid has tandem duplication in a nucleotide sequence of a juxtamembrane and is useful for diagnosis of leukemia; a polypeptide encoded by the nucleic acid; an antibody capable of specifically binding to a region encoded by the nucleic acid having tandem duplication occurring in a nucleotide sequence of a juxtamembrane; a nucleic acid capable of specifically binding to the nucleic acid having tandem duplication occurring in a nucleotide sequence of a juxtamembrane; a method for detection of the nucleic acid encoding a receptor protein kinase; and a kit therefor. A nucleic acid encoding a receptor protein kinase, wherein the nucleic acid has tandem duplication in a nucleotide sequence of a juxtamembrane; a polypeptide encoded by the nucleic acid; an antibody capable of specifically binding to the portion of the polypeptide; a nucleic acid capable of specifically binding to the nucleic acid; a method for detection of the nucleic acid; and a kit for detection.

The present invention discloses a safe and environmentally friendly cichorium intybus chloroplast transformation system establishment method, which comprises: (1) establishing a high frequency regeneration system of a cichorium intybus leaf explant; (2) constructing a safe and environmentally friendly cichorium intybus chloroplast site-specific integration expression vector; and (3) adopting a gene gun bombardment method to transform the cichorium intybus explant, and carrying out three rounds of resistance screening to obtain the chloroplast transgene strain. According to the present invention, the novel safe selection marker gene PMI is adopted to replace the traditional antibiotic marker gene aadA to construct the chloroplast site-specific integration expression vector and establish the cichorium intybus chloroplast transformation system, wherein the system has advantages of high screening efficiency, high exogenous gene expression level, strong transgenic plant bio-safety and the like; and receptor types of chloroplast transformation are broadened, and technical platforms are built for genetic improvement on cichorium intybus, or application of cichorium intybus chloroplast as a bioreactor to produce animal oral vaccines, medical proteins and the like.

The invention provides a prophylactic agent or therapeutic agent for fibrodysplasia ossificans progressiva, containing as an active ingredient a binding inhibitor that inhibits interaction between activin and activin A receptor type I (ACVR1), or an expression suppressor that suppresses expression of activin.

The invention belongs to the field of macromolecular photoelectronic materials, and discloses a main chain donor-side chain receptor type conjugated polymer and a preparation method thereof as well asapplication to a single-component organic solar battery. The structure of the conjugated polymer is as follows: as shown in the specification, wherein n is a positive integer less than or equal to 1,000,000, a is a positive integer from 3 to 40, R is methyl, methoxyl, nitrile group or a fluorine atom, R1, R2, R3 and R4 are the same or different alkyl chains, and A is an electron-deficient conjugated unit structure which is at least one of diazosulfide and a derivative thereof, benzotriazolimide and a derivative thereof, naphthalene dithiadiazole and a derivative thereof, and naphthylene ditrizole and a derivative thereof. A main chain of the conjugated polymer disclosed by the invention is of a P-type conjugated structure, and narrow band gap light absorption type n-type small molecules are introduced into a side chain; the main chain donor-side chain receptor type conjugated polymer is applied to the single-component organic solar battery, and no donors and no receptors are needed; separation of a nano phase of an active layer of a battery instrument can be effectively enhanced by adjusting the length of an alkyl chain on the side chain, and the instrument efficiency is improved.

A gene related to a susceptibility of infection and asthma—the Protein-Tyrosine Phosphatase Receptor-type Delta (PTPRD) gene—a method of detecting the asthma-associated gene, a method of predicting the occurrence of asthma, a method of identifying asthma-associated alleles in PTPRD gene, a method of screening PTPRD for drugs useful in the treatment of asthma, and antibodies specific for PTPRD variants and their use in diagnostic assays.